[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100578412":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":26,"responsibleParty":41,"collaborators":10,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":10,"eligibilityCriteria":49,"healthyVolunteers":45,"sex":50,"minAge":51,"maxAge":10,"enrollmentInfo":52,"targetDuration":10,"studyType":55,"phases":10,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":29,"whyStopped":10,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},{"fullName":5,"class":6},"Eisai Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"LEQEMBI",null,"Patients with alzheimer's disease treated with LEQEMBI in accordance with the approved prescribing information by a physician in routine clinical practice (postmarketing). Data will be collected from the JOY-ALZ registry.",[13],"Other: No Intervention",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"OTHER","No Intervention","This is a non-interventional study.",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Eisai Korea Inc. Medical department Serena SoYoun Kwon","CONTACT","+82-2-3451-5533","s-kwon@eisaikorea.com",[27],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":10},"Eisai Trial Site #1","RECRUITING","Nutley","New Jersey","07110","United States","US",{"type":36,"coordinates":37},"Point",[38,39],-74.15987,40.82232,{"lat":39,"lon":38},{"type":42,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100578412","a-postmarketing-study-of-leqembi-in-south-korean-participants-with-alzheimers-disease-100578412",false,"NCT06810960","A Postmarketing Study of LEQEMBI in South Korean Participants With Alzheimer's Disease","A 6-Year Postmarketing Safety and Clinical Outcome Study of LEQEMBI® in the Treatment of Alzheimer's Disease Using Real-World Data From South Korean Patients Enrolled Into the South Korean JOint RegistrY for ALZheimer's Treatment and Diagnostics (JOY-ALZ) Registry","Inclusion Criteria:\n\n* Enrolled in JOY-ALZ before the decision to treat with LEQEMBI\n* The clinical decision to treat with LEQEMBI has already been made\n* Provides written informed consent for the use of medical information to be shared with Eisai Korea Inc.\n\nExclusion Criteria:\n\n* Currently participating in an interventional clinical study","ALL","19 Years",{"count":53,"type":54},3000,"ESTIMATED","OBSERVATIONAL","The primary purpose of this study is to evaluate safety of LEQEMBI in the real-world clinical setting as reported by events of amyloid-related imaging abnormalities (ARIA)-edema (ARIA-E), ARIA-hemosiderin deposition (ARIA-H), symptomatic ARIA-E, symptomatic ARIA-H, and intracerebral hemorrhage (ICH) greater-than 1 centimeter (cm) in patients treated with LEQEMBI.",[58],"Alzheimer's Disease",[58,9,60],"ARIA","2026-04-16",{"date":63,"type":64},"2026-04-21","ACTUAL",{"date":66,"type":64},"2025-02-24",{"date":68,"type":54},"2029-09-30",{"name":70,"class":6},"Eisai Korea Inc.",1]